Consistent with the CUT&Tag findings, western blot analysis also indicated that the YAP inhibitor combined with trastuzumab therapy contributed to GC progression via the AKT/mTOR and ERK/mTOR pathways (Fig. 5g, h). Here, MAPK1 is linked to gastric cancer.